Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Sell
41
NPCE Quote, Financials, Valuation and Earnings
Last price:
$11.85
Seasonality move
:
31.16%
Day range:
$11.80 - $13.19
52-week range:
$5.45 - $18.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.20x
P/B ratio:
15.99x
Volume:
351.3K
Avg. volume:
403.3K
1-year change:
85.42%
Market cap:
$388M
Revenue:
$79.9M
EPS (TTM):
-$0.84
Analysts' Opinion
-
Consensus RatingNeuroPace has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.13, NeuroPace has an estimated upside of 44.76% from its current price of $11.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $11.83.
Fair Value
-
According to the consensus of 6 analysts, NeuroPace has 44.76% upside to fair value with a price target of $17.13 per share.
NPCE vs. S&P 500
-
Over the past 5 trading days, NeuroPace has underperformed the S&P 500 by -10.5% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
NeuroPace does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
NeuroPace has grown year-over-year revenues for 11 quarters straight. In the most recent quarter NeuroPace reported revenues of $22.5M.
Earnings Growth
-
NeuroPace has grown year-over-year earnings for 0 quarters straight. In the most recent quarter NeuroPace reported earnings per share of -$0.21.
Enterprise value:
381.5M
EV / Invested capital:
4.54x
Price / LTM sales:
4.20x
EV / EBIT:
--
EV / Revenue:
4.53x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-21.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$63.1M
Return On Assets:
-25.09%
Net Income Margin (TTM):
-29.42%
Return On Equity:
-186.98%
Return On Invested Capital:
-34.26%
Operating Margin:
-22.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $48.6M | $69.1M | $84.3M | $18.1M | $22.5M | |
| Gross Profit | $34.6M | $51.1M | $63.1M | $13.3M | $17.3M | |
| Operating Income | -$39.4M | -$26.4M | -$19.3M | -$7.5M | -$5.1M | |
| EBITDA | -$35.7M | -$21.1M | -$14.3M | -$6.2M | -$4M | |
| Diluted EPS | -$1.86 | -$1.18 | -$0.84 | -$0.32 | -$0.21 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $47.1M | $122.4M | $90.2M | $84.3M | $97.5M | |
| Total Assets | $50.3M | $129M | $106.3M | $98.9M | $110.2M | |
| Current Liabilities | $10.8M | $12.1M | $9.9M | $13.1M | $14.7M | |
| Total Liabilities | $206.8M | $66.2M | $78.8M | $84.5M | $85.9M | |
| Total Equity | -$156.4M | $62.8M | $27.5M | $14.3M | $24.3M | |
| Total Debt | $53.2M | $50.1M | $53.9M | $58M | $59.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$35.2M | -$17.5M | -$17.9M | -$7.5M | -$7.5M | |
| Cash From Investing | $34.2M | $15.4M | $6.6M | $2.4M | -$37K | |
| Cash From Financing | $234K | $8.5M | $25.4M | $72K | $21.1M | |
| Free Cash Flow | -$35.6M | -$17.7M | -$18.1M | -$7.6M | -$7.5M | |
NPCE
Sector
Market Cap
$388M
$34.2M
Price % of 52-Week High
62.35%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
85.42%
-35.99%
Beta (5-Year)
--
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$12.99
200-day SMA
Buy
Level
$10.67
Bollinger Bands (100)
Sell
Level
11.03 - 14.51
Chaikin Money Flow
Buy
Level
5.1M
20-day SMA
Sell
Level
$14.71
Relative Strength Index (RSI14)
Sell
Level
38.46
ADX Line
Sell
Level
28.41
Williams %R
Buy
Level
-84.2784
50-day SMA
Sell
Level
$12.91
MACD (12, 26)
Sell
Level
-0.23
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
2.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.4737)
Sell
CA Score
(Annual)
Level (-2.6176)
Buy
Beneish M-Score
(Annual)
Level (-2.9629)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (4.4249)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
Stock Forecast FAQ
In the current month, NPCE has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The NPCE average analyst price target in the past 3 months is $17.13.
-
Where Will NeuroPace Stock Be In 1 Year?
According to analysts, the consensus estimate is that NeuroPace share price will rise to $17.13 per share over the next 12 months.
-
What Do Analysts Say About NeuroPace?
Analysts are divided on their view about NeuroPace share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that NeuroPace is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is NeuroPace's Price Target?
The price target for NeuroPace over the next 1-year time period is forecast to be $17.13 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is NPCE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for NeuroPace is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NPCE?
You can purchase shares of NeuroPace via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase NeuroPace shares.
-
What Is The NeuroPace Share Price Today?
NeuroPace was last trading at $11.85 per share. This represents the most recent stock quote for NeuroPace. Yesterday, NeuroPace closed at $11.83 per share.
-
How To Buy NeuroPace Stock Online?
In order to purchase NeuroPace stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is up 29.48% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is up 20.55% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 17.78% over the past day.
